Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread

Criscitiello, C; Corti, C; De Laurentiis, M; Bianchini, G; Pistilli, B; Cinieri, S; Castellan, L; Arpino, G; Conte, P; Di Meco, F; Gennari, A; Guarneri, V; Visani, L; Livi, L; Marchetti, P; Puglisi, F; Viale, G; Del Mastro, L; De Placido, S; Curigliano, G

Criscitiello, C (通讯作者)，European Inst Oncol, Div Early Drug Dev Innovat Therapy, IRCCS, Via Ripamonti 435, I-20133 Milan, Italy.

CANCER TREATMENT REVIEWS, 2023; 120 ():

Abstract

Approximately 20% of breast cancers (BCs) overexpress human epidermal growth factor receptor 2 (HER2), a transmembrane glycoprotein with tyrosine kina......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索